Xenotransplantation is set for spectacular growth.

A supporting infrastructure of high growth businesses will accompany xenotransplantation.

future.bio is building the infrastructure to launch the xenotransplantation industry.

We see waves of growth in xenotransplantation.

Those underserved from the current organ shortage will be the first wave.

Those excluded by strict waitlist criteria will follow.

As benefits begin to outweigh risks, those who are in the early stages of organ failure can be transplanted.

Applying the typical hype curve to xenotransplantation indicates we are in the productivity phase.

From an initial technology trigger in the 1990’s, the curve peaked then decayed rapidly. New gene editing technology in the early 2010’s addressed the core need to improve efficiency.

Advances in treatment protocols have improved early results and new clinical trials are targeting patients most likely to have long term benefits.

Deactivating, or knocking out, incompatible pig genes is one way to improve the potential of engraftment.

Human transgenes added to the pig’s genome may also improve the odds of engraftment of a pig organ.

CRISPR has made gene editing of the pig more efficient and a new generation of tools called base editors are being applied to make fine adjustments to further improve compatibility.

Accelerated regulatory pathways are appropriate for any life saving advances as big as xenotransplantation.

Clinical trials are underway now in the US and China and are likely to start in other countries.

The existing oversight for the human donor organ transplant industry offers a very quick path to commercialization as soon as a viable treatment for organ failure is proved.